MedKoo Cat#: 208391 | Name: WOBE437

Description:

WARNING: This product is for research use only, not for human or veterinary use.

WOBE437 is a selective endocannabinoid reuptake inhibitor which reduces disease progression in a mouse model of multiple sclerosis

Chemical Structure

WOBE437
WOBE437
CAS#2108100-73-6

Theoretical Analysis

MedKoo Cat#: 208391

Name: WOBE437

CAS#: 2108100-73-6

Chemical Formula: C22H33NO3

Exact Mass: 359.2460

Molecular Weight: 359.51

Elemental Analysis: C, 73.50; H, 9.25; N, 3.90; O, 13.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
WOBE-437, wobe437
IUPAC/Chemical Name
(2E,4E)-N-[2-(3,4-Dimethoxyphenyl)ethyl]dodeca-2,4-dienamide
InChi Key
LAHLFCSEHHJQRN-AQASXUMVSA-N
InChi Code
InChI=1S/C22H33NO3/c1-4-5-6-7-8-9-10-11-12-13-22(24)23-17-16-19-14-15-20(25-2)21(18-19)26-3/h10-15,18H,4-9,16-17H2,1-3H3,(H,23,24)/b11-10+,13-12+
SMILES Code
CCCCCCC/C=C/C=C/C(NCCC1=CC=C(OC)C(OC)=C1)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 359.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, Chicca A. Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis. ACS Pharmacol Transl Sci. 2021 Mar 26;4(2):765-779. doi: 10.1021/acsptsci.0c00214. PMID: 33860200; PMCID: PMC8033750. 2: Mäder P, Bartholomäus R, Nicolussi S, Baumann A, Weis M, Chicca A, Rau M, Simão AC, Gertsch J, Altmann KH. Synthesis and Biological Evaluation of Endocannabinoid Uptake Inhibitors Derived from WOBE437. ChemMedChem. 2021 Jan 8;16(1):145-154. doi: 10.1002/cmdc.202000153. Epub 2020 May 26. PMID: 32369259. 3: Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J. The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. Front Mol Neurosci. 2018 May 28;11:180. doi: 10.3389/fnmol.2018.00180. PMID: 29910713; PMCID: PMC5992379. 4: Gagestein B, Stevens AF, Fazio D, Florea BI, van der Wel T, Bakker AT, Fezza F, Dulk HD, Overkleeft HS, Maccarrone M, van der Stelt M. Chemical Proteomics Reveals Off-Targets of the Anandamide Reuptake Inhibitor WOBE437. ACS Chem Biol. 2022 May 20;17(5):1174-1183. doi: 10.1021/acschembio.2c00122. Epub 2022 Apr 28. PMID: 35482948; PMCID: PMC9127799. 5: Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Dalghi Gens M, Lutz B, Schiöth HB, Soeberdt M, Abels C, Charles RP, Altmann KH, Gertsch J. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E5006-E5015. doi: 10.1073/pnas.1704065114. Epub 2017 Jun 5. PMID: 28584105; PMCID: PMC5488949. 6: Miller S, Daily L, Dharla V, Gertsch J, Malamas MS, Ojima I, Kaczocha M, Ogasawara D, Straiker A. Endocannabinoid metabolism and transport as targets to regulate intraocular pressure. Exp Eye Res. 2020 Dec;201:108266. doi: 10.1016/j.exer.2020.108266. Epub 2020 Sep 23. PMID: 32979397; PMCID: PMC8054225.